1.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
by Balar, Arjun V, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.67-76
2.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
by Powles, Thomas
Nature medicine, 2019-11, Vol.25 (11), p.1706-1714
3.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 s...
by Balar, Arjun V
The lancet oncology, 2017-11, Vol.18 (11), p.1483-1492
4.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
by Banerji, Udai, Prof
The lancet oncology, 2019, Vol.20 (8), p.1124-1135
5.
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial
by Kleinmann, Nir
The lancet oncology, 2020-06, Vol.21 (6), p.776-785
6.
Chemoimmunotherapy in urothelial cancer: concurrent or sequential?
by Zengin, Zeynep B
The lancet oncology, 2021-07, Vol.22 (7), p.894-896
7.
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
by van Dijk, Nick
Nature medicine, 2020-12, Vol.26 (12), p.1839-1844
8.
Molecular Subtypes of Bladder Cancer
by McConkey, David J
Current oncology reports, 2018-08-20, Vol.20 (10), p.77-7
9.
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
by Powles, T
Nature medicine, 2021-12, Vol.27 (12), p.2200-2211
10.
New mitomycin formulation for low-grade upper tract urothelial cancer
by Dreicer, Robert
The lancet oncology, 2020-06, Vol.21 (6), p.735-736
11.
European Society of Medical Oncology 2019 Congress
by Lai, Cheryl
The Lancet. Oncology, 2019-11, Vol.20 (11), p.1488-1488
12.
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
by Powles, Thomas
Nature medicine, 2021-05, Vol.27 (5), p.793-801
13.
Urothelial carcinoma in COVID-19: lessons from a pandemic and their impact on clinical practice
by Tayeh, Georges Abi
Future oncology (London, England), 2021-08-01, Vol.17 (32), p.4233-4235
14.
Critical treatment choices for patients with platinum-refractory urothelial carcinoma
by Lotan, Yair
The lancet oncology, 2020-01, Vol.21 (1), p.11-13
15.
Ramucirumab plus pembrolizumab: can we make the maths work?
by Klempner, Samuel J
The lancet oncology, 2019, Vol.20 (8), p.1041-1043
16.
Global consequences of the US FDA's accelerated approval of cancer drugs
by Akhade, Amol
The lancet oncology, 2022-02, Vol.23 (2), p.201-203
17.
Enfortumab vedotin for cisplatin-ineligible urothelial cancer
by Pignot, Geraldine
The lancet oncology, 2021-06, Vol.22 (6), p.748-749
18.
Cabozantinib as a choice for platinum-refractory metastatic urothelial cancer
by Kikuchi, Eiji
The lancet oncology, 2020-08, Vol.21 (8), p.1005-1006
19.
Chemotherapy for advanced urothelial cancer: end of the beginning?
by Dreicer, Robert
The lancet oncology, 2017, Vol.18 (5), p.567-569
20.
Upper Tract Urinary Cancer Recurrence after Radical Cystectomy: Risk Assessment of Intraoperative Frozen Section
by Nientiedt, Malin
Urologia internationalis, 2022-02-04, p.1-9
